SAT0120 EVALUATION OF THE RISK OF OVERALL MALIGNANCY AND MALIGNANT LYMPHOMA WITH METHOTREXATE AND BIOLOGICAL AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS BASED ON THE IORRA COHORT DURING A 14-YEAR OBSERVATION PERIOD
Background: While dramatic progress has been made in this decade with treatments for rheumatoid arthritis (RA), such as methotrexate (MTX) and biological agents, concern about the safety, including the occurrence of malignancy, of these highly effective drugs still exists in daily clinical practice. There has not been an evident association between the use of biological agents and the occurrence of malignancy in most reports from clinical trials 1 and observational studies 2 , although MTX use might be associated with the development of malignant lymphoma, called MTX-associated lymphoproliferative disorder 3 , in patients with RA. In an analysis of risk factors for overall and site-specific malignancies in Japanese patients with RA, higher disease activity was identified to be a risk factor for overall malignancies (hazard ratio [HR] 1.10, 95% CI 1.02-1.19), suggesting that tight control of RA disease activity would reduce the occurrence of malignancies in patients with RA 4 . However, the risk of malignancies with RA treatments including MTX and biological agents was not assessed in that analysis. Objectives: We investigated the association between the occurrence of malignancies (overall and malignant lymphoma) and drug use (MTX and biological agents) in a large observational cohort of Japanese patients with RA over a long-term period. Methods: Among Japanese patients with RA enrolled in the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) cohort from April 2000 to September 2013, data for all malignancies were extracted from patients' self-reports and confirmed by medical records. Data for malignancies occurring in patients who dropped out of the IORRA study during the subsequent three months were also collected from medical information from affiliated hospitals. We analysed whether MTX and biological agents were risk factors for overall malignancy and malignant lymphoma using a marginal structural Cox proportional hazards model 5 adjusted for age, gender, smoking history, body mass index, RA disease duration, rheumatoid factor positivity and disease activity (28-joint disease activity score). Results: Among 11,106 Japanese patients with RA representing 68,483 personyears, 507 overall malignancies, including 68 malignant lymphomas, were confirmed. Neither MTX nor biological agent use was a significant risk factor for overall malignancy, with an HR (95% CI) of 1.18 (0.77-1.81) and 1.01 (0.65-1.57), respectively, or for malignant lymphoma, with an HR (95% CI) of 1.17 (0.55-2.48) and 1.26 (0.43-3.64), respectively. Conclusions: The use of MTX and biological agents was not significantly associated with the occurrence of overall malignancy or malignant lymphoma during long-term longitudinal observation of Japanese patients with RA. Background: Health status in rheumatoid arthritis (RA), as measured by Health Assessment Questionnaire -Disability Index (HAQ-DI), has been established as a relevant quantitative measure to assess and monitor the disease (1). Current RA therapy has shown improvement in patient-reported outcomes, but more data on specific factors influencing health status are needed (2). Objectives: To assess the relationship between functional disability and clinical factors in patients with RA, using the HAQ score. Methods: Cross-sectional study in patients with RA according to the ACR classification criteria from three Brazilian University Hospitals. Demographic and comprehensive clinical data, including components of metabolic profile were collected. Blood pressure, weight and height were determined in the assessment visit and recent laboratory data were assessed from medical records. Disease activity was evaluated by the Disease Activity Score in 28 joints (DAS28) and functional disability was assessed by the HAQ-DI, considering an index>0.5 as disability. All analyses were performed using Stata for MAC 12.0 software. Variables that achieved a p-value<0.3 in the univariate analysis were considered as candidates to take part of a multivariate binomial logistic model, and in this model, variables were considered as statistically significant at the 0.05 significance level (3). Results: 453 patients were included, 380 (83.9%) women, mean age 55.7 (±12) years, 356 (79.1%) Caucasian, and mean disease duration of 13.3 (±9) years. Methotrexate were used by 73.5% of the sample. Mean DAS28 was 3.9 (±1.4), mean HAQ score was 1.11 (±0.77), and 23.9% of the patients had HAQ score>0.5. Dyslipidemia, diabetes mellitus (DM), high blood pressure (HBP) and family history of premature cardiovascular disease occurred in 28.6%, 12.8%, 51% and 21.4% of the patients, respectively. Mean body mass index (BMI) was 27.1 (±4.9) kg/m 2 . In multivariate analysis age, DAS28, tobacco use, and diabetes mellitus were independently associated with HAQ>0.5 (TABLE 1). DAS28 -disease activity score in 28 joints; BMI -body mass index; OR -odds ratio.
Conclusions:
Our results depicted that distinct factors could reflect in the functional status response in RA patients. This is relevant since it may influence the clinicaly important difference when evaluating the HAQ response in populations with diverse cultural features and different comorbidities prevalence.
